<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01230983</url>
  </required_header>
  <id_info>
    <org_study_id>9404</org_study_id>
    <secondary_id>U10CA030969</secondary_id>
    <secondary_id>POG-9404</secondary_id>
    <secondary_id>CDR0000064664</secondary_id>
    <nct_id>NCT01230983</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma</brief_title>
  <acronym>T-Cell #4</acronym>
  <official_title>Intensive Treatment For T-CELL Acute Lymphoblastic Leukemia and Advanced Stage Lymphoblastic Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells. Dexrazoxane
      may lessen the side effects of chemotherapy.

      PURPOSE: Randomized phase III trial to compare combination chemotherapy with or without
      dexrazoxane and with or without high-dose methotrexate in patients with acute lymphoblastic
      leukemia or advanced lymphoblastic non-Hodgkin's lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine, in a randomized trial, the effectiveness of high-dose methotrexate
      when added to a multiagent chemotherapy backbone (the Dana Farber Cancer Institute regimen,
      protocol DFCI-87001) proven effective in T-cell acute lymphoblastic leukemia (T-ALL) and
      advanced lymphoblastic non-Hodgkin's lymphoma (NHL). II. Determine the role of dexrazoxane in
      preventing cardiotoxicity in children with T-ALL and advanced lymphoblastic NHL treated with
      an anthracycline-based regimen. III. Study the biology of T-cell lymphoid malignancies by
      accumulating data on the concurrent ALL classification study (POG-9400) and analyzing the
      data relative to outcome. IV. Evaluate the correlation of minimal residual disease (using the
      TAL 1 proto-oncogene) with event-free survival. V. Determine the role of p53 and p16 tumor
      suppressor genes in T-ALL. VI. Determine whether drug sensitivity profiles of blast cells to
      doxorubicin, methotrexate, and cytarabine correlate with initial response and subsequent
      relapse.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      disease category (acute lymphoblastic leukemia (ALL) with no CNS disease vs. ALL with CNS
      disease vs. non-Hodgkin's lymphoma (NHL) with no CNS disease vs. NHL with CNS disease),
      gender, race (Caucasian vs. African American vs. Hispanic). Patients are randomized to one of
      four treatment arms. ARM I: During induction therapy, patients receive vincristine IV once
      daily on days 1, 8, 15, and 22, oral prednisone three times a day on days 1-21, doxorubicin
      IV daily on days 1, 2, and 22, methotrexate IV once, at least 8 hours after doxorubicin on
      day 2, and oral mercaptopurine daily on days 22-35. Patients receive triple intrathecal
      therapy (TIT) consisting of methotrexate, cytarabine, and hydrocortisone on weeks 1, 3, 4, 5,
      and 6. Patients with CNS 2 or 3 disease receive TIT on week 2. During weeks 7-33, patients
      receive consolidation therapy consisting of vincristine IV once every 3 weeks, oral
      prednisone three times a day over 5 days, every 3 weeks, doxorubicin IV once every 3 weeks,
      oral mercaptopurine daily for 14 days, every 3 weeks, and asparaginase intramuscularly (IM)
      weekly on weeks 7-26. Patients receive TIT on week 10 and 22 (on week 16 for patients with
      CNS 2 or 3 disease). Patients receive radiotherapy beginning on week 22. During weeks 34-108,
      patients receive continuation therapy consisting of vincristine IV once every 3 weeks, oral
      prednisone three times a day over 5 days, every 3 weeks, methotrexate IV or IM weekly
      (omitted during TIT) and oral mercaptopurine daily for 14 days, every 3 weeks. Patients
      receive TIT on weeks 40, 58, 76, and 94. Arm II: Patients receive induction therapy as in Arm
      I with an addition of dexrazoxane IV given prior to doxorubicin on days 1, 2, and 22.
      Patients receive consolidation therapy as in Arm I with an addition of dexrazoxane IV given
      prior to doxorubicin once every 3 weeks. Patients receive continuation therapy as in Arm I.
      Arm III: Patients receive induction therapy as in Arm I in addition to high dose methotrexate
      IV on week 4 and leucovorin calcium IV or orally every 6 hours for 7 doses beginning 36 hours
      after high dose methotrexate. Patients receive consolidation therapy as in Arm I in addition
      to high dose methotrexate IV on weeks 7, 10, and 13 followed by leucovorin calcium as in
      induction therapy. Patients receive continuation therapy as in Arm I. Arm IV: Patients
      receive induction therapy and consolidation therapy as in Arms I, II, and III. Patients
      receive continuation therapy as in Arm I. Treatment continues for up to 108 weeks in the
      absence of disease progression or unacceptable toxicity. Patients are followed every 2 months
      for 1 year, every 4 months for 3 years, then every 6 months for 2 years.

      PROJECTED ACCRUAL: A total of 494 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1996</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <primary_completion_date type="Actual">September 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Continuous Remission</measure>
    <time_frame>Time to failure for any cause among patients achieving a complete response</time_frame>
    <description>Since all patients receive the same induction, the endpoint will be CCR , i.e. complete continuous remission (the time to failure for any cause among patients achieving a complete response)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Abnormalities in the 31 week and the year 3 echocardiograms</measure>
    <time_frame>1 year off therapy</time_frame>
    <description>Endpoint will be abnormalities in the 31 week and the year 3 echocardiograms (i.e. year 1 off therapy). Secondarily, we shall compare the CCR rates for the two treatment regimens, in a two sided fashion.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">573</enrollment>
  <condition>Cardiac Toxicity</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment 1: (No HD MTX / No Zinecard)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Closed 09/2000 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), methotrexate/cytarabine), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, IT methotrexate /cytarabine radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), IT methotrexate/cytarabine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 2: (No HD MTX / Zinecard)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Closed 09/2000 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), methotrexate/cytarabine, dexrazoxane hydrochloride (Zinecard or DZR)), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, dexrazoxane hydrochloride (Zinecard or DZR), IT methotrexate /cytarabine, radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), IT methotrexate/cytarabine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 3: (HD MTX / No Zinecard)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Closed 09/2001 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), leucovorin calcium (LCV), HD methotrexate/cytarabine), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, leucovorin calcium (LCV), HD methotrexate /cytarabine radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), HD methotrexate/cytarabine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 4: (HD MTX / Zinecard)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Closed 09/2001 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), leucovorin calcium (LCV), HD methotrexate/cytarabine, dexrazoxane hydrochloride (Zinecard or DZR)), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, HD methotrexate /cytarabine, dexrazoxane hydrochloride (Zinecard or DZR), radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), HD methotrexate/cytarabine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>asparaginase</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment 1: (No HD MTX / No Zinecard)</arm_group_label>
    <arm_group_label>Treatment 2: (No HD MTX / Zinecard)</arm_group_label>
    <arm_group_label>Treatment 3: (HD MTX / No Zinecard)</arm_group_label>
    <arm_group_label>Treatment 4: (HD MTX / Zinecard)</arm_group_label>
    <other_name>E. coli</other_name>
    <other_name>Elspar</other_name>
    <other_name>NSC #10922</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment 1: (No HD MTX / No Zinecard)</arm_group_label>
    <arm_group_label>Treatment 2: (No HD MTX / Zinecard)</arm_group_label>
    <arm_group_label>Treatment 3: (HD MTX / No Zinecard)</arm_group_label>
    <arm_group_label>Treatment 4: (HD MTX / Zinecard)</arm_group_label>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>AraC</other_name>
    <other_name>Cytosar</other_name>
    <other_name>NSC #06387</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexrazoxane hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment 2: (No HD MTX / Zinecard)</arm_group_label>
    <arm_group_label>Treatment 4: (HD MTX / Zinecard)</arm_group_label>
    <other_name>DZR</other_name>
    <other_name>ADR-529</other_name>
    <other_name>ZINECARD</other_name>
    <other_name>ICRF-187</other_name>
    <other_name>NSC #169780</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment 1: (No HD MTX / No Zinecard)</arm_group_label>
    <arm_group_label>Treatment 2: (No HD MTX / Zinecard)</arm_group_label>
    <arm_group_label>Treatment 3: (HD MTX / No Zinecard)</arm_group_label>
    <arm_group_label>Treatment 4: (HD MTX / Zinecard)</arm_group_label>
    <other_name>Doxorubicin</other_name>
    <other_name>NSC #123127</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment 3: (HD MTX / No Zinecard)</arm_group_label>
    <arm_group_label>Treatment 4: (HD MTX / Zinecard)</arm_group_label>
    <other_name>LCV</other_name>
    <other_name>Wellcovorin</other_name>
    <other_name>citrovorum factor</other_name>
    <other_name>folinic acid</other_name>
    <other_name>NSC #003590</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mercaptopurine</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment 1: (No HD MTX / No Zinecard)</arm_group_label>
    <arm_group_label>Treatment 2: (No HD MTX / Zinecard)</arm_group_label>
    <arm_group_label>Treatment 3: (HD MTX / No Zinecard)</arm_group_label>
    <arm_group_label>Treatment 4: (HD MTX / Zinecard)</arm_group_label>
    <other_name>6-MP</other_name>
    <other_name>Purinethol</other_name>
    <other_name>NSC #000755</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment 1: (No HD MTX / No Zinecard)</arm_group_label>
    <arm_group_label>Treatment 2: (No HD MTX / Zinecard)</arm_group_label>
    <arm_group_label>Treatment 3: (HD MTX / No Zinecard)</arm_group_label>
    <arm_group_label>Treatment 4: (HD MTX / Zinecard)</arm_group_label>
    <other_name>MTX</other_name>
    <other_name>amethopterin</other_name>
    <other_name>NSC #000740</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment 1: (No HD MTX / No Zinecard)</arm_group_label>
    <arm_group_label>Treatment 2: (No HD MTX / Zinecard)</arm_group_label>
    <arm_group_label>Treatment 3: (HD MTX / No Zinecard)</arm_group_label>
    <arm_group_label>Treatment 4: (HD MTX / Zinecard)</arm_group_label>
    <other_name>Deltasone</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Liquid Pred</other_name>
    <other_name>NSC #010023</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>therapeutic hydrocortisone</intervention_name>
    <description>Given IT</description>
    <arm_group_label>Treatment 1: (No HD MTX / No Zinecard)</arm_group_label>
    <arm_group_label>Treatment 2: (No HD MTX / Zinecard)</arm_group_label>
    <arm_group_label>Treatment 3: (HD MTX / No Zinecard)</arm_group_label>
    <arm_group_label>Treatment 4: (HD MTX / Zinecard)</arm_group_label>
    <other_name>hydrocortisone sodium succinate</other_name>
    <other_name>Solu-cortef</other_name>
    <other_name>NSC #010483</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment 1: (No HD MTX / No Zinecard)</arm_group_label>
    <arm_group_label>Treatment 2: (No HD MTX / Zinecard)</arm_group_label>
    <arm_group_label>Treatment 3: (HD MTX / No Zinecard)</arm_group_label>
    <arm_group_label>Treatment 4: (HD MTX / Zinecard)</arm_group_label>
    <other_name>VCR</other_name>
    <other_name>Oncovin</other_name>
    <other_name>NSC #067574</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Radiation to cranium</description>
    <arm_group_label>Treatment 1: (No HD MTX / No Zinecard)</arm_group_label>
    <arm_group_label>Treatment 2: (No HD MTX / Zinecard)</arm_group_label>
    <arm_group_label>Treatment 3: (HD MTX / No Zinecard)</arm_group_label>
    <arm_group_label>Treatment 4: (HD MTX / Zinecard)</arm_group_label>
    <other_name>XRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: T-cell acute lymphoblastic leukemia (ALL) Registration on current
        ALL classification study (POG-9400) required within 6 working days prior to entry DR-, T+
        DR-, T- or DR+, T+ eligible if T-cell ALL confirmed at the Johns Hopkins Reference
        Laboratory Biopsy-proven diffuse lymphoblastic lymphoma Murphy stage III/IV disease
        Registered on ALL classification study (POG-9400)

        PATIENT CHARACTERISTICS: Age: Over 12 months to under 22 years for T-ALL Under 22 years for
        lymphoma

        PRIOR CONCURRENT THERAPY: No prior therapy other than steroids or emergency mediastinal
        irradiation in patients with severe respiratory distress from mediastinal disease Steroid
        treatment allowed provided that physical examination and complete blood count with
        differential were performed immediately prior to beginning steroids and results of both are
        known
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara L. Asselin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>James P. Wilmot Cancer Center</affiliation>
  </overall_official>
  <reference>
    <citation>Cleaver AL, Beesley AH, Firth MJ, Sturges NC, O'Leary RA, Hunger SP, Baker DL, Kees UR. Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: a Children's Oncology Group study. Mol Cancer. 2010 May 12;9:105. doi: 10.1186/1476-4598-9-105.</citation>
    <PMID>20459861</PMID>
  </reference>
  <reference>
    <citation>Salzer WL, Devidas M, Carroll WL, Winick N, Pullen J, Hunger SP, Camitta BA. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group. Leukemia. 2010 Feb;24(2):355-70. doi: 10.1038/leu.2009.261. Epub 2009 Dec 17.</citation>
    <PMID>20016527</PMID>
  </reference>
  <reference>
    <citation>Matloub Y, Asselin BL, Stork LC, et al.: Outcome of children with T-Cell acute lymphoblastic leukemia (T-ALL) and standard risk (SR) features: results of CCG-1952, CCG-1991 and POG 9404. [Abstract] Blood 104 (11): A-680, 195a, 2004.</citation>
  </reference>
  <reference>
    <citation>Seibel NL, Asselin BL, Nachman JB, et al.: Treatment of high risk T-cell acute lymphoblastic leukemia (T-ALL): comparison of recent experience of the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG). [Abstract] Blood 104 (11): A-681, 2004.</citation>
  </reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2010</study_first_submitted>
  <study_first_submitted_qc>October 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2010</study_first_posted>
  <last_update_submitted>June 4, 2013</last_update_submitted>
  <last_update_submitted_qc>June 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III childhood lymphoblastic lymphoma</keyword>
  <keyword>stage IV childhood lymphoblastic lymphoma</keyword>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <keyword>T-cell childhood acute lymphoblastic leukemia</keyword>
  <keyword>cardiac toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Dexrazoxane</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Razoxane</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

